US20050064512A1 - Emitter-binding peptides that produce a change in the spectral emission properties of the emitter - Google Patents
Emitter-binding peptides that produce a change in the spectral emission properties of the emitter Download PDFInfo
- Publication number
- US20050064512A1 US20050064512A1 US10/887,231 US88723104A US2005064512A1 US 20050064512 A1 US20050064512 A1 US 20050064512A1 US 88723104 A US88723104 A US 88723104A US 2005064512 A1 US2005064512 A1 US 2005064512A1
- Authority
- US
- United States
- Prior art keywords
- emitter
- seq
- nos
- binding peptide
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 47
- 230000003595 spectral effect Effects 0.000 title claims abstract description 28
- 230000008859 change Effects 0.000 title claims abstract description 25
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 14
- 239000000427 antigen Substances 0.000 claims abstract description 20
- 102000036639 antigens Human genes 0.000 claims abstract description 20
- 108091007433 antigens Proteins 0.000 claims abstract description 20
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 19
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 19
- 230000003993 interaction Effects 0.000 claims abstract description 9
- 239000000975 dye Substances 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 39
- 230000008569 process Effects 0.000 claims description 34
- 238000010521 absorption reaction Methods 0.000 claims description 31
- 239000000126 substance Substances 0.000 claims description 23
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 20
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000010287 polarization Effects 0.000 claims description 6
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims description 5
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 claims description 5
- 229950000688 phenothiazine Drugs 0.000 claims description 5
- 239000001022 rhodamine dye Substances 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 125000005504 styryl group Chemical group 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 238000011002 quantification Methods 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- -1 for example Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 description 21
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 15
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 14
- 239000010931 gold Substances 0.000 description 14
- 229910052737 gold Inorganic materials 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 238000010367 cloning Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 0 [1*][N+]1=C(B=[2H])[Y]C2=C1C=CC([3*])=C2 Chemical compound [1*][N+]1=C(B=[2H])[Y]C2=C1C=CC([3*])=C2 0.000 description 6
- 238000006862 quantum yield reaction Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 235000017168 chlorine Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000005401 electroluminescence Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- AWZJFZMWSUBJAJ-UHFFFAOYSA-N OG-514 dye Chemical compound OC(=O)CSC1=C(F)C(F)=C(C(O)=O)C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)=C1F AWZJFZMWSUBJAJ-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 125000001309 chloro group Chemical class Cl* 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- HAFZTWYRKGACLU-UHFFFAOYSA-K tetrasulfocyanine Chemical compound [Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C(C)(C)C(\C=C\C=C(\C=C\C=C\3C(C4=CC(=CC=C4N/3CCS([O-])(=O)=O)S([O-])(=O)=O)(C)C)/C)=[N+](CCS([O-])(=O)=O)C2=C1 HAFZTWYRKGACLU-UHFFFAOYSA-K 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Definitions
- This invention relates to emitter-binding peptides that produce a change in the spectral emission properties of the emitter in the case of an interaction of its antigen-binding pocket with the emitter.
- the emitter-binding peptides of the invention are in particular components of antibodies and antibody fragments.
- in-vitro diagnostic measuring processes that are based on biological molecules, such as, e.g., peptides, proteins, antibodies or oligonucleotides, which have a high affinity for a substance that is to be determined.
- biological molecules such as, e.g., peptides, proteins, antibodies or oligonucleotides, which have a high affinity for a substance that is to be determined.
- proteins and peptides are preferably used, and antibodies and antibody fragments are especially preferably used.
- Certain in-vitro diagnostic processes are based on the combination of various antibodies against the substance that is to be determined, whereby one antibody is used for the separation of the substance that is to be determined from the study sample, and the other antibody carries the diagnostically detected signal molecule.
- the labeled antibody is optically detected [Grayeski, M. L., Anal. Chem. 1987, 59, 1243].
- the light-induced phosphorescence and the fluorescence can also be used as an optical property of molecules for diagnostic measuring processes.
- fluorescence as an optical property of molecules offers the advantage of high detection sensitivity and high linearity of the measuring signal over a large dynamic range.
- the anti-substance antibodies that are used fulfill different purposes. On the one hand, they are used for separating the substance that is to be determined from the sample, but on the other hand, they also fulfill the object of locating or positioning different signal transmitters that are used on the substance that is to be examined.
- To detect, e.g., an antibody in a sample primarily optical and radioactive measuring processes have been established, but also acoustic (see, e.g., Cooper, M. A. et al. Direct and Sensitive Detection of a Human Virus by Rupture Event Scanning. Nat Biotechnol. 2001 September; 19(9): 833-7) and magnetic measuring processes are known.
- the anti-substance antibody is labeled with a fluorophore. This labeling is carried out by specific and unspecific chemical coupling. The labeled antibody is added in excess to the study sample. This is necessary to bind all substance molecules that are to be examined.
- this process generally uses as a basis that one anti-substance antibody uses the separation of the substance that is to be examined and the second anti-substance antibody, which detects the study substance at another binding site, is labeled with a signaling molecule. In this way, a distortion of the measuring result by the unbonded, but signaling antibody can be avoided.
- This procedure is associated with an elevated methodical and technical expense and higher costs, produced by the separation step. The high technical expense, which prevents establishing this process for high-speed diagnosis, has proven especially disadvantageous, however.
- Antibodies and peptides that are directed against molecules of low molecular weight are already known. These also include antibodies and peptides against dye molecules. Simeonov, A. et al., in Science 2000, 290, 307-313 thus describe antibodies against stilbenes (“blue-fluorescent antibodies”). These antibodies catalyze specific photochemical isomerization processes and result in red-shifted absorption and fluorescence maxima in the UV-VIS spectral range (absorption shift maximum 12 nm, fluorescence shift 22 nm). Simeonov, A. et al., however, provide no reference whatsoever to a red shift while preserving the fluorescence quantum yield in the case of cyanine dyes in a wavelength range of 600-1200 nm.
- antibodies against various dyes are already commercially available, e.g., against fluorescein, tetramethylrhodamine, Texas Red, Alexa fluorine 488, BODIPY FL, Lucifer Yellow and Cascade Blue, Oregon Green (Molecular Probes Company, Inc., USA).
- fluorescein tetramethylrhodamine
- Texas Red Alexa fluorine 488
- BODIPY FL Lucifer Yellow and Cascade Blue
- Oregon Green Oregon Green
- emitter-binding peptides and especially specific antibodies that are more suitable for the above-mentioned measuring processes.
- especially emitter-binding peptides that would produce a red shift while preserving the fluorescence quantum yield with cyanine dyes in the wavelength range of 600-1200 nm would be advantageous.
- an emitter-binding peptide that is characterized in that the latter produces a change in the spectral emission properties of the emitter in the case of an interaction of its antigen binding pocket with the emitter
- a process for the production of an emitter-binding peptide according to the invention comprising the immunization of a suitable organism with an emitter, comprising a dye that is selected from the group of polymethine dyes, such as dicarbocyanine, tricarbocyanine, indotricarbocyanine, merocyanine, styryl, squarilium and oxonol dyes, and rhodamine dyes, phenoxazine or phenothiazine dyes and corresponding uses of an emitter-binding peptide, a nucleic acid, a host cell or an antibody or conjugate according to the invention as a diagnostic agent for in vitro diagnosis.
- Suitable embodiments are cited in the dependent claims
- a first aspect of this invention thus relates to an emitter-binding peptide, characterized in that the latter produces a change in spectral emission properties of the emitter in the case of an interaction of its antigen binding pocket with the emitter.
- the emitter comprises a dye that exhibits at least an absorption maximum and/or fluorescence maximum within the spectral range of 700 to 1000 nm, preferably at least an absorption maximum and fluorescence maximum within the spectral range of 750 to 900 nm.
- an emitter-binding peptide according to the invention, whereby the change in the emission properties of the part of the emitter is selected from a change in the polarization plane, the fluorescence intensity, the phosphorescence intensity, the fluorescence service life and a bathochromic shift of the absorption maximum and/or the fluorescence maximum.
- the invention is not limited to these special phenomena, however the term “change in the emission properties” within the scope of this invention is to comprise all physical phenomena or effects in which the high-energy radiation that occurs in the emitter is altered in its property and in this case this change is quantitatively dependent on the binding/non-binding of the substance-emitter conjugate or the substance-detecting agent-emitter-conjugate with its emitter-binding partner and the substance.
- the substance is, for example, a peptide, protein, oligonucleotide and in particular an antibody or an antibody fragment.
- the antibody fragments are fragments that comprise at least the antigen-binding areas that contain the so-called “complementarity-determining regions” (“CDRs”).
- CDRs complementarity-determining regions
- the antigen-binding areas most preferably comprise the complete variable chains VL and VH.
- the antibody or the antibody fragment is selected from polyclonal or monoclonal antibodies, humanized antibodies, Fab fragments, in particular monomeric Fab fragments, scFv fragments, synthetic and recombinant antibodies, scTCR chains and mixtures thereof.
- Especially preferred here in the case of the synthetic and recombinant antibodies or antibody fragments are those from an HuCAL library (WO 97/08320; Knappik, (2000), J. Mol. Biol. 296, 57-86; Krebs et al. J Immunol Methods. 2001 Aug. 1; 254(1-2): 67-84).
- antibody fragments can be present either as complete immunoglobulins or antibodies in one of the naturally occurring formats (IgA, IgD, IgE, IgG, IgM) or as antibody fragments, whereby the antibody fragments comprise at least the amino acid positions 4 to 103 for VL and 5 to 109 for VH, preferably the amino acid positions 3 to 107 for VL and 4 to 111 for VH and especially preferably the complete variable chains VL and VH (amino acid positions 1 to 109 for VL and 1 to 113 for VH) (numbering according to WO 97/08320).
- the antibody or the antibody fragment comprises in this case at least one of the CDR areas contained in the sequences SEQ-ID Nos.: 1, 2, 5, 6, 9, 10, 13, 14, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37 and 39 (VL: CDR1 positions 24-34, CDR2 positions 50-56, CDR3 positions 89-96; VH: CDR1 positions 26-35, CDR2 positions 50-65, CDR3 positions 95-102), especially VL CDR3 or VH CDR3.
- VL CDR1 positions 24-34, CDR2 positions 50-56, CDR3 positions 89-96
- VH CDR1 positions 26-35, CDR2 positions 50-65, CDR3 positions 95-102
- an antibody that comprises one of the variable chains VL that are contained in the sequences SEQ-ID Nos.: 2, 6, 10, 14, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37 and 39 or a variable chain VL that is contained in one of the sequences SEQ-ID Nos.: 1, 5, 9 and 13 (or a fragment of such an antibody).
- an antibody that comprises a VH/VL pair that is contained in the following sequence pairs: SEQ-ID Nos.: 1+2; SEQ-ID Nos.: 5+6; SEQ-ID Nos.: 9+10; SEQ-ID Nos.: 13+14; SEQ-ID Nos.: 5+17; SEQ-ID Nos.: 5+19; SEQ-ID Nos.: 5+37; SEQ-ID Nos.: 9+21; SEQ-ID Nos.: 9+23; SEQ-ID Nos.: 9+25; SEQ-ID Nos.: 9+27; SEQ-ID Nos.: 9+29; SEQ-ID Nos.: 9+31; SEQ-ID Nos.: 9+33; SEQ-ID Nos.: 9+39; SEQ-ID Nos.: 13+35 (or a fragment of such an antibody).
- one or more of the CDR areas can be exchanged, for example specifically for CDR areas of other antibodies that already show the properties according to the invention or else by libraries of corresponding CDR sequences (see for this purpose the optimization in Example 1), which either produce completely random variations or contain a more or less strong preference (tendency) in the direction of specific amino acids or combinations thereof.
- One skilled in the art is also able, moreover, to exchange complete variable chains in the same way for corresponding chains of other defined antibodies or for diverse libraries of such chains.
- processes to exchange one or more amino acid radicals in the CDRs specifically by mutagenesis are known to one skilled in the art.
- nucleic acid molecules that code one of the antibodies or an antibody fragment according to the invention.
- these are nucleic acid molecules that code one of the variable chains VL that is contained in the sequences SEQ-ID Nos.: 2, 6, 10, 14, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37 and 39 or a variable chain VH that is contained in sequences SEQ-ID Nos.: 1, 5, 9 and 13.
- Especially preferred in this case are the sequences according to SEQ-ID Nos.: 3, 4, 7, 8, 11, 12, 15, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 and 40.
- the emitter-binding peptide of this invention optimally exhibits a binding affinity of less than 50 nm and preferably of less than 10 nm.
- the emitter comprises a dye that has at least an absorption maximum and/or fluorescence maximum within the spectral range of 700 to 1000 nm, preferably at least an absorption maximum and fluorescence maximum within the spectral range of 750 to 900 nm.
- the bathochromic shift of the dye is selected such that the shift of the absorption maximum and/or fluorescence maximum to higher wavelengths is carried out after interaction with the agent to detect the emitter by a value of greater than 15 nm, preferably greater than 25 nm and most preferably by approximately 30 nm. In this case, a shift does not necessarily have to be considered as such, which is a property of the dye.
- the shift would be measured as a change of an emission value matched to the die, i.e., at a certain singular wavelength.
- suitable optical agents for measurement that are known to one skilled in the art are provided. This also applies for the measurement of the change in the polarization plane, the fluorescence intensity, the phosphorescence intensity, the fluorescence service life and a bathochromic shift of the absorption maximum and/or the fluorescence maximum.
- the emitter that is used comprise a dye that is selected from the group of polymethine dyes, such as dicarbocyanine, tricarbocyanine, indotricarbocyanine, merocyanine, styryl, squarilium, and oxonol dyes, and rhodamine dyes, phenoxazine or phenothiazine dyes.
- polymethine dyes such as dicarbocyanine, tricarbocyanine, indotricarbocyanine, merocyanine, styryl, squarilium, and oxonol dyes, and rhodamine dyes, phenoxazine or phenothiazine dyes.
- the emitter of the substance-emitter-conjugate according to the invention can comprise a cyanine dye of general formula (I) in which D stands for a radical (II) or (III) whereby the position that is labeled with the star means the point of linkage with radical B and can stand for the group (IV), (V), (VI), (VII) or (VIII) in which R 1 and R 2 , independently of one another, represent a C 1 -C 4 -sulfoalkyl chain, a saturated or unsaturated, branched or straight-chain C 1 -C 50 -alkyl chain, which optionally is interrupted by 0 to 15 oxygen atoms and/or by 0 to 3 carbonyl groups and/or can be substituted with 0 to 5 hydroxy groups; R 3 and R 4 , independently of one another, stand for the group —COOE 1 , —CONE 1 E 2 , —NHCOE 1 , —NHCONHE 1 , —NE 1 E 2
- the emitter can form conjugates with substances.
- those of general formula S-E are used as substance-emitter conjugates, in which S stands for a substance that is to be examined and E stands for an emitter that comprises a part that reacts with a change in the emission properties in an interaction with the agents for detecting the emitter.
- S stands for a substance that is to be examined
- E stands for an emitter that comprises a part that reacts with a change in the emission properties in an interaction with the agents for detecting the emitter.
- structural components of the conjugates according to the invention i.a., dyes that have at least an absorption maximum and a fluorescence maximum within the spectral range of 600 to 1200 nm are suitable. In this case, dyes with at least an absorption maximum and a fluorescence maximum within the spectral range of 700 to 1000 nm are preferred.
- Dyes that meet these criteria are, for example, those of the following classes: polymethine dyes, such as dicarbocyanine, tricarbocyanine, merocyanine and oxonol dyes, rhodamine dyes, phenoxazine or phenothiazine dyes, tetrapyrrole dyes, especially benzoporphyrins, chlorines, bacteriochlorines, pheophorbides, bacteriopheophorbides, purpurines and phthalocyanines.
- polymethine dyes such as dicarbocyanine, tricarbocyanine, merocyanine and oxonol dyes, rhodamine dyes, phenoxazine or phenothiazine dyes, tetrapyrrole dyes, especially benzoporphyrins, chlorines, bacteriochlorines, pheophorbides, bacteriopheophorb
- Preferred dyes are the cyanine dyes with absorption maxima between 750 and 900 nm, and with special advantage indotricarbocyanines.
- Structural components of the conjugates according to the invention are also the substances whose determination of concentration is to be carried out by means of the process according to the invention.
- antigens such as proteins, peptides, nucleic acids, oligonucleotides, blood components, serum components, lipids, pharmaceutical agents and compounds of low molecular weight, especially sugars, dyes or other compounds with a molecular weight of under 500 Dalton.
- Preferred dyes are the cyanine dyes with absorption maxima of between 750 and 900 nm, and with special advantage indotricarbocyanines.
- the dyes contain structural elements, via which the covalent coupling to the substance structures is carried out.
- the latter are, e.g., linkers with carboxy groups, amino groups, and hydroxy groups.
- the latter can be carried out in a different way and is directed mainly according to the type of characteristic change in the spectral properties of the emitter (e.g., fluorophore).
- the spectral properties of the emitter e.g., fluorophore
- other properties such as, e.g., the photon service life, the polarization, and the bleaching behavior, can also be used for optical measurement.
- antibodies against fluorophores which are able to change their spectral properties in the UV range after binding the fluorophore, are already known to one skilled in the art.
- fluorophore By binding a fluorophore in the antigen binding pocket of an antibody, primarily the fluorescence intensity, the absorption maximum, the emission maximum, and the photon service life can be changed [Simeonov, A., et al., Science (2000) 307-313].
- These known antibodies are directed against emitters (fluorophores), however, which have their absorption and fluorescence emission in the visible and UV range of the light.
- Another aspect of this invention relates to the use of an emitter-binding peptide according to the invention for in vitro diagnosis.
- the emitter-binding peptide according to the invention can also be present in a diagnostic kit, optionally together with other adjuvants.
- all of these kits according to the invention can contain special instructions and documents (e.g., calibration curves, directions for quantification, etc.).
- FIG. 1 The CysDisplay-Screening vector pMORPH23 (vector map and sequence),
- FIG. 2 The expression vector pMORPHX9 MS (vector map and sequence), and
- FIG. 3 Absorption spectrum (left) and fluorescence spectrum of the dye from Example 2 with and without the presence of antibody MOR02965 in PBS.
- HuCAL GOLD is a fully synthetic, modular human antibody library in the Fab antibody fragment format. HuCAL GOLD is based on the HuCAL-consensus-antibody genes that were described for the HuCAL-scFv1 library (WO 97/08320; Knappik, (2000), J. Mol. Biol. 296, 57-86; Krebs et al. J Immunol Methods. 2001 Aug. 1; 254(1-2): 67-84). In HuCAL GOLD, all six CDR areas are diversified by the use of so-called trinucleotide mutagenesis (Virnekals et al. (1994) Nucleic Acids Res. 1994 Dec.
- the original HuCAL master genes were constructed with their authentic N-termini: VL ⁇ 1: QS (CAGAGC), VL ⁇ 2: QS (CAGAGC), and VL ⁇ 3: SY (AGCTAT). These sequences are found in WO 97/08320.
- these two amino acid radicals were changed in “DI” to facilitate the cloning (EcoRI site). These radicals were preserved in the production of HuCAL-Fab1 and HuCAL GOLD.
- All HuCAL libraries therefore contain VL ⁇ genes with the EcoRV interface GATATC (DI) at the 5′-end.
- All HuCAL kappa genes master genes and all genes in the libraries) in any case contain DI at the 5′-end, since these represent the authentic N-termini (WO 97/08320).
- the corresponding sequences are found in WO 97/08320.
- the amino acid Q (CAG) was incorporated in all VH genes at this position 1.
- phagemids were produced and concentrated by infection of E. coli TOP10F′ cells from the HuCAL GOLD antibody library or from the maturation libraries by means of helper phages.
- the HuCAL GOLD or the maturation libraries (in the TOP10F′ cells) were cultivated in 2 ⁇ YT medium with 34 ⁇ g/ml of chloramphenicol/10 ⁇ g/ml of tetracycline/1% glucose at 37° C. up to an OD 600 of 0.5. Then, the infection was carried out with VCSM13 helper phages at 37° C.
- the infected cells were pelletized and resuspended in 2 ⁇ YT/34 ⁇ g/ml of chloramphenicol/10 ⁇ g/ml of tetracycline/50 ⁇ g/ml of kanamycin/0.25 mmol of IPTG and cultivated overnight at 22° C.
- the phages were precipitated 2 ⁇ 0 with PEG from the supernatant and harvested by centrifuging (Ausubel (1998) Current Protocols in Molecular Biology. John Wiley Sons, Inc., New York, USA).
- the phages were resuspended in PBS/20% glycerol and stored at ⁇ 80° C.
- the phagemid amplification between the individual selection rounds was carried out as follows: log-phase E. coli TG1 cells were infected with selected phages and flattened out on LB-agar plates with 1% glucose/34 ⁇ g/ml of chloramphenicol. After incubation overnight, the bacteria colonies were scraped off, newly cultivated and infected with VCSM13 helper phages.
- the purified and concentrated phagemids of the HuCAL GOLD antibody library were used in a standard selection process.
- As antigens BSA- or transferrin-coupled ZK203468 were used alternately.
- the antigens were taken up in PBS and applied at concentrations of 50 ⁇ g/ml on MaxisorpTM microtiter plates F96 (Nunc).
- the Maxisorp plates were incubated overnight at 4° C. (“coating”). After the Maxisorp plates were blocked with 5% milk powder in PBS, about 2E+13 HuCAL GOLD phages were added to the antigen-loaded, blocked-off wells and incubated there overnight or for two hours at room temperature.
- bonded phages were eluted with 20 mmol of DTT or 100 ⁇ mol of unconjugated ZK203468. Altogether, three successive selection rounds were carried out, whereby the phage amplification was carried out between the selection rounds, as described above.
- the Fab-coding inserts of the isolated HuCAL clones were subcloned in the expression vector pMORPHX9 _MS (see FIG. 2 ) to facilitate the subsequent expression of the Fab fragments.
- the purified plasmid-DNA of the selected HuCAL Fab clones was digested with the restriction enzymes XbaI and EcoRI.
- the Fab-coding insert was purified and ligated into the correspondingly digested vector pMORPHX9_MS. This cloning step results in the Fab-expressing vector pMORPHX9_Fab_MS.
- Fab fragments, which are expressed by this vector carry two C-terminal tags (Myc tag and Strep tag II) for purification and detection.
- the plasmid-DNA of the four parenteral clones MOR02628, MOR02965, MOR02969 and MOR02977 was digested with the restriction enzymes EcoRI and XbaI, and the complete Fab-insert from expression vector pMORPHX9_MS that was produced was subcloned in the correspondingly cut display vector pMORPH23. This step is necessary to prepare the geneIII, which is used in the presentation of the Fab-fragment on the phage surface.
- the four parenteral clones (now in pMORPH23) were digested with BpiI and SphI.
- the LCDR3 region and the constant Clambda area were removed from the vector backbone.
- the corresponding vector-DNA fragment was isolated and purified.
- Several ⁇ g of vector-DNA and compatible insert-DNA were ligated in a molar ratio of 1:2 with T4-DNA-ligase and transformed into electrocompetent TOP10F′ cells after a purification step. In this case, library sizes of 5E+8 to approximately 1E+9 clones were achieved per parenteral antibody.
- the libraries on which clones MOR02628, MOR02969 and MOR02977 were based were combined (“Pool”).
- the MOR02965 library was treated separately (“Lead”).
- the corresponding phagemids were produced by infection with VCSM13 helper phages by means of these TOP10F′-maturation libraries.
- the purified and concentrated phagemids of the “lead” and “pool” libraries were used in a maturation-selection process under stringent conditions (long washing periods, displacement by purified, parenteral Fab proteins).
- As antigens BSA- or transferrin-coupled ZK203468 were used alternately. These antigens were taken up in PBS and applied at low concentrations of 100-250 ng/ml on MaxisorpTM microtiter plates F96 (Nunc). The Maxisorp plates were incubated overnight at 4° C. (“coating”).
- the purified and concentrated phagemids of the “lead” and “pool” libraries were used in addition in a second maturation-selection process under stringent conditions (long washing periods, displacement by purified, parenteral Fab proteins or free dye).
- biotin-conjugated ZK203468 was used (alternately with alkyl or ether linkers). These antigens were taken up in PBS and mixed at low concentrations of 60 or 12 ng/ml with the approximately 2E+11 phages. The antigen-phage solutions were incubated overnight or for 2 hours at room temperature.
- the Fab-coding inserts of the isolated HuCAL clones were subcloned in the expression vector pMORPHX9_MS to facilitate the subsequent expression.
- the purified plasmid-DNA of the selected HuCAL Fab clones was digested with the restriction enzymes XbaI and EcoRI.
- the Fab-coding insert was purified and ligated into the correspondingly digested vector pMORPHX9_MS. This cloning step results in the Fab-expressing vector pMORPHX9_Fab_MS.
- Fab fragments, which are expressed by this vector carry two C-terminal tags (Myc tag and Strep tag II) for purification and detection.
- the clones were isolated from the selections and screened in ELISAs in 384-well format.
- ZK203468-BSA was applied on the ELISA-microtiter plates.
- the Fab fragments that are to be examined were added as non-purified bacterial lysates.
- identical screening plates with bacterial lysate and additional free dye were mixed in two different concentrations.
- the inhibition of the Fab binding to the solid phase that resulted in this case owing to the unconjugated dye indicated antibodies that do not specifically detect the dye conjugate but rather only the free dye.
- isolated clones were characterized exactly in solution-inhibition tests in the ELISA format and the Luminex device, and their affinities for Fuji 6-4 were determined.
- the “multiple cloning site” of the vector pCDNA3.1+ (Invitrogen) is removed (NheI/ApaI), and a placeholder that is compatible with the restriction interfaces of the HuCAL design is used for the ligation of the leader sequence (NheI/EcoRI), the VH domains of the Fab fragment (MunI/), and the constant immunoglobulin regions (BlpI/ApaI).
- the leader sequence (EMBL 83133) is equipped with a contact sequence (Kozak, 1987).
- the constant regions of human IgG (PIR J00228), IgG4 (EMBL K01316), and serum-IgA1 (EMBL J00220) are divided up into overlapping oligonucleotides with a length of, for example, 70 bases. “Silent mutations” are introduced to remove the reaction interfaces that are not compatible with the HuCAL design. The oligonucleotides are linked by “overlap extension-PCR”.
- the heavy chain of the Fab fragment is cut out via MfeI/BlpI and ligated into the vector, which is opened with EcoRI/BlpI.
- EcoRI (g/aattc) and MfeI (c/aattg) have two compatible cohesive ends (aatt), and the sequence of the original MfeI interface in the Fab fragments is changed from: c/aattg to g/aattg to the ligation in the IgG expression vector, by which, on the one hand, both the MfeI interface and the EcoRI interface are destroyed, and, on the other hand, an amino acid exchange from Q (codon: caa) to E (codon: gaa) takes place.
- the “multiple cloning site” of pCDNA3.1/Zeo+ (Invitrogen) is replaced by two different placeholders.
- the k-placeholder contains restriction interfaces for the incorporation of a k-leader sequence (NheI/EcoRV), the HuCAL Fab Vk domains (EcoRV/BsiWI), and the constant region of the k-chain (BsiWI/ApaI).
- the corresponding interfaces in the 1-placeholder are NheI/EcoRV (1-leader), EcoRV/HpaI (V1-domains), and HpaI/ApaI (constant region 1-chain).
- the k-leader (EMBL Z00022) as well as the 1-leader (EMBL J00241) are both provided with Kozak sequences.
- the constant regions of human k-(EMBL L00241) and 1-chains (EMBL M18645) are both assembled by “overlap extension-PCR,” as described above.
- IgG-expressing CHO cells CHO-K1 cells are co-transfixed with an equimolar mixture of expression vectors for the heavy and light IgG chains. Doubly resistant transfectants are selected with 600 mg/ml of G418 and 300 mg/ml of Zeocin (Invitrogen) followed by limited dilution. The supernatant of individual clones is checked for IgG expression by “capture-ELISA.” Positive clones are cultured in RPMI-1640 medium, which is provided with 10% “ultra-low IgG-FCS” (Life Technologies). After the pH of the supernatant is set at 8.0 and after sterile filtration, the solution is subjected to a standard protein A-column chromatography (Poros 20 A, PE Biosystems).
Abstract
Description
- This application claims the benefit of the filing date of U.S. Provisional Application Ser. No. 60/487,234 filed Jul. 16, 2003.
- This invention relates to emitter-binding peptides that produce a change in the spectral emission properties of the emitter in the case of an interaction of its antigen-binding pocket with the emitter. The emitter-binding peptides of the invention are in particular components of antibodies and antibody fragments.
- For the diagnostic detection of substances and determination of their concentration, now used in many cases are in-vitro diagnostic measuring processes that are based on biological molecules, such as, e.g., peptides, proteins, antibodies or oligonucleotides, which have a high affinity for a substance that is to be determined. For this purpose, proteins and peptides are preferably used, and antibodies and antibody fragments are especially preferably used.
- Certain in-vitro diagnostic processes, such as, e.g., electrochemoluminescence, are based on the combination of various antibodies against the substance that is to be determined, whereby one antibody is used for the separation of the substance that is to be determined from the study sample, and the other antibody carries the diagnostically detected signal molecule. In the case of the diagnostic process of electrochemoluminescence, the labeled antibody is optically detected [Grayeski, M. L., Anal. Chem. 1987, 59, 1243].
- In addition to the electroluminescence, the light-induced phosphorescence and the fluorescence can also be used as an optical property of molecules for diagnostic measuring processes. Compared to electroluminescence and phosphorescence, in particular fluorescence as an optical property of molecules offers the advantage of high detection sensitivity and high linearity of the measuring signal over a large dynamic range.
- To detect the fluorescence of a fluorophore, various measuring processes were developed that use different principles within the fluorescence processes. Established measuring processes use, e.g., the weakening of polarized light (fluorescence polarization=FP), the measurement of the photon service life (fluorescence service life measurement —FLM), the bleaching properties (fluorescence photobleaching recovery—FPR) and the energy transfer between various fluorophores (fluorescence-resonance-energy transfer—FRET) [Williams, A. T., et al., Methods Immunol. Anal. 1993, 1, 466; Youn, H. J. et al., Anal. Biochem. 1995 Oswald, B. et al., Anal. Biochem. 2000, 280, 272; Szollosi, J. et al., Cytometry 1998, 34, 159].
- Other detection processes are based on a change in the polarization plane or the detection of phosphorescence.
- In the above-mentioned processes, the anti-substance antibodies that are used fulfill different purposes. On the one hand, they are used for separating the substance that is to be determined from the sample, but on the other hand, they also fulfill the object of locating or positioning different signal transmitters that are used on the substance that is to be examined. To detect, e.g., an antibody in a sample, primarily optical and radioactive measuring processes have been established, but also acoustic (see, e.g., Cooper, M. A. et al. Direct and Sensitive Detection of a Human Virus by Rupture Event Scanning. Nat Biotechnol. 2001 September; 19(9): 833-7) and magnetic measuring processes are known. The optical measuring processes have gained the maximum distribution [Nakamura, R. M., Dito, W. R., Tucker, E. S. (Eds.). Immunoassays: Clinical Laboratory Techniques for the 1980s. A. R. Liss, New York. Edwards, R. (ed.). Immunoassays: Essential Data, 1996, Wiley Europe].
- In the majority of the already available measuring processes, the anti-substance antibody is labeled with a fluorophore. This labeling is carried out by specific and unspecific chemical coupling. The labeled antibody is added in excess to the study sample. This is necessary to bind all substance molecules that are to be examined. In addition, this process generally uses as a basis that one anti-substance antibody uses the separation of the substance that is to be examined and the second anti-substance antibody, which detects the study substance at another binding site, is labeled with a signaling molecule. In this way, a distortion of the measuring result by the unbonded, but signaling antibody can be avoided. This procedure, however, is associated with an elevated methodical and technical expense and higher costs, produced by the separation step. The high technical expense, which prevents establishing this process for high-speed diagnosis, has proven especially disadvantageous, however.
- Antibodies and peptides that are directed against molecules of low molecular weight are already known. These also include antibodies and peptides against dye molecules. Simeonov, A. et al., in Science 2000, 290, 307-313 thus describe antibodies against stilbenes (“blue-fluorescent antibodies”). These antibodies catalyze specific photochemical isomerization processes and result in red-shifted absorption and fluorescence maxima in the UV-VIS spectral range (absorption shift maximum 12 nm, fluorescence shift 22 nm). Simeonov, A. et al., however, provide no reference whatsoever to a red shift while preserving the fluorescence quantum yield in the case of cyanine dyes in a wavelength range of 600-1200 nm.
- Watt, R. M. et al. (Immunochemistry 1977, 14, 533-541) describe the spectral properties of the already known anti-fluorescein-antibody constructs. After binding the fluorescein, the antibody produces a shift of the absorption and fluorescence maximum in the visible spectral range, but only by 12 nm or 5 nm. In addition, a strong reduction of the fluorescence quantum yield (by about 90%) is carried out.
- Rozinov, M. N. et al. (Chem. Biol. 1998, 5, 713-728) describe the selection of 12-mer peptides from phage libraries, which bind the dyes Texas Red, Rhodamine Red, Oregon Green 514 and fluorescein. For Texas Red, a red shift of the absorption and fluorescence was observed, but only by 2.8 nm or 1.4 nm.
- In addition, antibodies against various dyes are already commercially available, e.g., against fluorescein, tetramethylrhodamine, Texas Red, Alexa fluorine 488, BODIPY FL, Lucifer Yellow and Cascade Blue, Oregon Green (Molecular Probes Company, Inc., USA). These are, however, polyclonal IgG antibodies for bioanalytical purposes, which have cross reactivities that are to some extent uncontrollable and are not produced from a strict selection process.
- There is a further need for improved emitter-binding peptides and especially specific antibodies that are more suitable for the above-mentioned measuring processes. In this case, especially emitter-binding peptides that would produce a red shift while preserving the fluorescence quantum yield with cyanine dyes in the wavelength range of 600-1200 nm would be advantageous.
- This object is achieved according to the invention by an emitter-binding peptide that is characterized in that the latter produces a change in the spectral emission properties of the emitter in the case of an interaction of its antigen binding pocket with the emitter, a process for the production of an emitter-binding peptide according to the invention, comprising the immunization of a suitable organism with an emitter, comprising a dye that is selected from the group of polymethine dyes, such as dicarbocyanine, tricarbocyanine, indotricarbocyanine, merocyanine, styryl, squarilium and oxonol dyes, and rhodamine dyes, phenoxazine or phenothiazine dyes and corresponding uses of an emitter-binding peptide, a nucleic acid, a host cell or an antibody or conjugate according to the invention as a diagnostic agent for in vitro diagnosis. Suitable embodiments are cited in the dependent claims.
- A first aspect of this invention thus relates to an emitter-binding peptide, characterized in that the latter produces a change in spectral emission properties of the emitter in the case of an interaction of its antigen binding pocket with the emitter.
- Preferred is an emitter-binding peptide according to the invention, whereby the emitter comprises a dye that exhibits at least an absorption maximum and/or fluorescence maximum within the spectral range of 700 to 1000 nm, preferably at least an absorption maximum and fluorescence maximum within the spectral range of 750 to 900 nm.
- Further preferred is an emitter-binding peptide according to the invention, whereby the change in the emission properties of the part of the emitter is selected from a change in the polarization plane, the fluorescence intensity, the phosphorescence intensity, the fluorescence service life and a bathochromic shift of the absorption maximum and/or the fluorescence maximum. The invention is not limited to these special phenomena, however the term “change in the emission properties” within the scope of this invention is to comprise all physical phenomena or effects in which the high-energy radiation that occurs in the emitter is altered in its property and in this case this change is quantitatively dependent on the binding/non-binding of the substance-emitter conjugate or the substance-detecting agent-emitter-conjugate with its emitter-binding partner and the substance. In an embodiment, the substance is, for example, a peptide, protein, oligonucleotide and in particular an antibody or an antibody fragment. Within the scope of this invention, the antibody fragments are fragments that comprise at least the antigen-binding areas that contain the so-called “complementarity-determining regions” (“CDRs”). In this case, the antigen-binding areas most preferably comprise the complete variable chains VL and VH.
- In an especially preferred aspect of the emitter-binding peptide according to this invention, the antibody or the antibody fragment is selected from polyclonal or monoclonal antibodies, humanized antibodies, Fab fragments, in particular monomeric Fab fragments, scFv fragments, synthetic and recombinant antibodies, scTCR chains and mixtures thereof.
- Especially preferred here in the case of the synthetic and recombinant antibodies or antibody fragments are those from an HuCAL library (WO 97/08320; Knappik, (2000), J. Mol. Biol. 296, 57-86; Krebs et al. J Immunol Methods. 2001 Aug. 1; 254(1-2): 67-84). These can be present either as complete immunoglobulins or antibodies in one of the naturally occurring formats (IgA, IgD, IgE, IgG, IgM) or as antibody fragments, whereby the antibody fragments comprise at least the amino acid positions 4 to 103 for VL and 5 to 109 for VH, preferably the
amino acid positions 3 to 107 for VL and 4 to 111 for VH and especially preferably the complete variable chains VL and VH (amino acid positions 1 to 109 for VL and 1 to 113 for VH) (numbering according to WO 97/08320). - In a preferred embodiment, the antibody or the antibody fragment comprises in this case at least one of the CDR areas contained in the sequences SEQ-ID Nos.: 1, 2, 5, 6, 9, 10, 13, 14, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37 and 39 (VL: CDR1 positions 24-34, CDR2 positions 50-56, CDR3 positions 89-96; VH: CDR1 positions 26-35, CDR2 positions 50-65, CDR3 positions 95-102), especially VL CDR3 or VH CDR3. Especially preferred in this case is an antibody that comprises one of the variable chains VL that are contained in the sequences SEQ-ID Nos.: 2, 6, 10, 14, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37 and 39 or a variable chain VL that is contained in one of the sequences SEQ-ID Nos.: 1, 5, 9 and 13 (or a fragment of such an antibody). Most preferred is an antibody that comprises a VH/VL pair that is contained in the following sequence pairs: SEQ-ID Nos.: 1+2; SEQ-ID Nos.: 5+6; SEQ-ID Nos.: 9+10; SEQ-ID Nos.: 13+14; SEQ-ID Nos.: 5+17; SEQ-ID Nos.: 5+19; SEQ-ID Nos.: 5+37; SEQ-ID Nos.: 9+21; SEQ-ID Nos.: 9+23; SEQ-ID Nos.: 9+25; SEQ-ID Nos.: 9+27; SEQ-ID Nos.: 9+29; SEQ-ID Nos.: 9+31; SEQ-ID Nos.: 9+33; SEQ-ID Nos.: 9+39; SEQ-ID Nos.: 13+35 (or a fragment of such an antibody). Especially preferred in this case are the Fab fragments MOR02628, MOR02965, MOR02977, MOR02969, MOR03263, MOR03325, MOR03285, MOR03201, MOR03267, MOR03268, MOR03292, MOR03294, MOR03295, MOR03309, MOR03293 and MOR03291. Starting from the thus described antibodies according to the invention, various possibilities to obtain new modified antibodies that also show the properties according to the invention follow in an obvious way for one skilled in the art.
- It is known to one skilled in the art that especially the CDR areas both of the heavy chain and the light chain are responsible for the affinity as well as the selectivity and specificity. In this case, especially the CDR3 area of VH and the CDR3 area of VL play a role, followed by CDR2 of VH and CDR1 of VL, while CDR1 of VH and CDR2 of VL in most cases play a subordinate role. To optimize the affinity as well as the selectivity and specificity of the antibodies, therefore, in particular the CDR areas are suggested (see also, e.g., Schier et al., J. Mol. Biol. (1996) 263, 551). In this case, for example, one or more of the CDR areas can be exchanged, for example specifically for CDR areas of other antibodies that already show the properties according to the invention or else by libraries of corresponding CDR sequences (see for this purpose the optimization in Example 1), which either produce completely random variations or contain a more or less strong preference (tendency) in the direction of specific amino acids or combinations thereof. One skilled in the art is also able, moreover, to exchange complete variable chains in the same way for corresponding chains of other defined antibodies or for diverse libraries of such chains. In addition, processes to exchange one or more amino acid radicals in the CDRs specifically by mutagenesis are known to one skilled in the art. The identification of such changing amino acid radicals is carried out here, e.g., based on a comparison of the sequences of various antibodies and the identification of preserved or at least highly homologous radicals in the corresponding positions. In the changes to the CDRs, in this case one skilled in the art also has knowledge of so-called “canonical structures” (Al-Lazikani et al., J. Mol. Biol. (2000) 295, 979); Knappik et al. J. Mol. Biol. (2000) 296, 57), which have an influence on the three-dimensional arrangement of the CDR areas, and the optimization strategies corresponding to the design can be considered.
- Moreover, techniques also to change the skeleton regions of antibodies or antibody fragments to obtain more stable or more expressible molecules are well known to one skilled in the art (WO 92/01787; Nieba et al. (1997) Protein Eng. 10, 435; Ewert et al. (2003) Biochemistry 42, 1517).
- In addition to these already described strategies for modification of antibodies or antibody fragments, one skilled in the art, with knowledge of the antibodies according to the invention and the measuring processes that are described in this application, is also able to perform additional changes to the amino acid sequence or the composition of the described antibodies and to decide, by using the described assays and measuring process, whether modified antibodies have been produced whose properties match those that distinguish the antibodies according to the invention.
- Another aspect of this invention relates to nucleic acid molecules that code one of the antibodies or an antibody fragment according to the invention. In a preferred embodiment, in this case these are nucleic acid molecules that code one of the variable chains VL that is contained in the sequences SEQ-ID Nos.: 2, 6, 10, 14, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37 and 39 or a variable chain VH that is contained in sequences SEQ-ID Nos.: 1, 5, 9 and 13. Especially preferred in this case are the sequences according to SEQ-ID Nos.: 3, 4, 7, 8, 11, 12, 15, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 and 40.
- The emitter-binding peptide of this invention optimally exhibits a binding affinity of less than 50 nm and preferably of less than 10 nm.
- Another aspect is an emitter-binding peptide of this invention, whereby the emitter comprises a dye that has at least an absorption maximum and/or fluorescence maximum within the spectral range of 700 to 1000 nm, preferably at least an absorption maximum and fluorescence maximum within the spectral range of 750 to 900 nm. The bathochromic shift of the dye is selected such that the shift of the absorption maximum and/or fluorescence maximum to higher wavelengths is carried out after interaction with the agent to detect the emitter by a value of greater than 15 nm, preferably greater than 25 nm and most preferably by approximately 30 nm. In this case, a shift does not necessarily have to be considered as such, which is a property of the dye. Usually, the shift would be measured as a change of an emission value matched to the die, i.e., at a certain singular wavelength. For this purpose, suitable optical agents for measurement that are known to one skilled in the art are provided. This also applies for the measurement of the change in the polarization plane, the fluorescence intensity, the phosphorescence intensity, the fluorescence service life and a bathochromic shift of the absorption maximum and/or the fluorescence maximum.
- For the emitter-binding peptides according to the invention, it is preferred that the emitter that is used comprise a dye that is selected from the group of polymethine dyes, such as dicarbocyanine, tricarbocyanine, indotricarbocyanine, merocyanine, styryl, squarilium, and oxonol dyes, and rhodamine dyes, phenoxazine or phenothiazine dyes. In general, the emitter of the substance-emitter-conjugate according to the invention can comprise a cyanine dye of general formula (I)
in which D stands for a radical (II) or (III)
whereby the position that is labeled with the star means the point of linkage with radical B and can stand for the group (IV), (V), (VI), (VII) or (VIII)
in which R1 and R2, independently of one another, represent a C1-C4-sulfoalkyl chain, a saturated or unsaturated, branched or straight-chain C1-C50-alkyl chain, which optionally is interrupted by 0 to 15 oxygen atoms and/or by 0 to 3 carbonyl groups and/or can be substituted with 0 to 5 hydroxy groups; R3 and R4, independently of one another, stand for the group —COOE1, —CONE1E2, —NHCOE1, —NHCONHE1, —NE1E2, —OE1, —OSO3E1, —SO3E1, —SO2NHE1 or -E1 , whereby E1 and E2, independently of one another, represent a hydrogen atom, a C1-C4-sulfoalkyl chain, a saturated or unsaturated, branched or straight-chain C1-C50-alkyl chain, which optionally is interrupted by 0 to 15 oxygen atoms and/or by 0 to 3 carbonyl groups and/or is substituted with 0 to 5 hydroxy groups, R5 stands for a hydrogen atom, a methyl, ethyl or propyl group or a fluorine, chlorine, bromine or iodine atom, b means the number 2 or 3, and X and Y independently stand for O, S, ═C(CH3)2 or —(CH═CH)—, as well as salts and solvates of these compounds. - It was possible to find, surprisingly enough, that after highly affine binding of an antibody to a cyanine dye with absorption and fluorescence in the near-infrared spectral range (>750 nm), a shift of the absorption maximum and fluorescence maximum by about 30 nm to higher wavelengths was carried out (bathochromic shift). With use of this principle, it is thus possible, for example, via a large concentration range, to detect directly and spectrally separately a signal from a whole-blood sample, whereby the signal behaves linearly with respect to the concentration of the substance that is to be determined.
- The emitter can form conjugates with substances. Within the scope of this invention, those of general formula
S-E
are used as substance-emitter conjugates, in which S stands for a substance that is to be examined and E stands for an emitter that comprises a part that reacts with a change in the emission properties in an interaction with the agents for detecting the emitter. As structural components of the conjugates according to the invention, i.a., dyes that have at least an absorption maximum and a fluorescence maximum within the spectral range of 600 to 1200 nm are suitable. In this case, dyes with at least an absorption maximum and a fluorescence maximum within the spectral range of 700 to 1000 nm are preferred. Dyes that meet these criteria are, for example, those of the following classes: polymethine dyes, such as dicarbocyanine, tricarbocyanine, merocyanine and oxonol dyes, rhodamine dyes, phenoxazine or phenothiazine dyes, tetrapyrrole dyes, especially benzoporphyrins, chlorines, bacteriochlorines, pheophorbides, bacteriopheophorbides, purpurines and phthalocyanines. - Preferred dyes are the cyanine dyes with absorption maxima between 750 and 900 nm, and with special advantage indotricarbocyanines. Structural components of the conjugates according to the invention are also the substances whose determination of concentration is to be carried out by means of the process according to the invention.
- These are selected from, for example, antigens, such as proteins, peptides, nucleic acids, oligonucleotides, blood components, serum components, lipids, pharmaceutical agents and compounds of low molecular weight, especially sugars, dyes or other compounds with a molecular weight of under 500 Dalton.
- Preferred dyes are the cyanine dyes with absorption maxima of between 750 and 900 nm, and with special advantage indotricarbocyanines.
- The dyes contain structural elements, via which the covalent coupling to the substance structures is carried out. The latter are, e.g., linkers with carboxy groups, amino groups, and hydroxy groups.
- In the case of an optical measurement, the latter can be carried out in a different way and is directed mainly according to the type of characteristic change in the spectral properties of the emitter (e.g., fluorophore). Generally preferred is a detection of the shift of the absorption wavelength and emission wavelength or the measurement of the absorption and/or fluorescence intensity at a wavelength that for the most part detects the portion of the emitter that is bonded to the antibody. Depending on the change in the spectral properties of the antibody-bonded fluorophore, other properties, such as, e.g., the photon service life, the polarization, and the bleaching behavior, can also be used for optical measurement.
- The special advantage of fluorophores in the spectral range of near-infrared light lies in the low rate of shadowing by components of the blood. In this respect, deep penetration is made possible without the signal to be detected being relatively changed to any major extent.
- Moreover, antibodies against fluorophores, which are able to change their spectral properties in the UV range after binding the fluorophore, are already known to one skilled in the art. By binding a fluorophore in the antigen binding pocket of an antibody, primarily the fluorescence intensity, the absorption maximum, the emission maximum, and the photon service life can be changed [Simeonov, A., et al., Science (2000) 307-313]. These known antibodies are directed against emitters (fluorophores), however, which have their absorption and fluorescence emission in the visible and UV range of the light.
- Another aspect of this invention relates to the use of an emitter-binding peptide according to the invention for in vitro diagnosis.
- For this purpose, the emitter-binding peptide according to the invention can also be present in a diagnostic kit, optionally together with other adjuvants. In addition, all of these kits according to the invention can contain special instructions and documents (e.g., calibration curves, directions for quantification, etc.).
- The invention is now to be described in more detail below based on examples and the attached figures and sequences, without, however, being limited thereto. Here:
-
FIG. 1 : The CysDisplay-Screening vector pMORPH23 (vector map and sequence), -
FIG. 2 : The expression vector pMORPHX9 MS (vector map and sequence), and -
FIG. 3 : Absorption spectrum (left) and fluorescence spectrum of the dye from Example 2 with and without the presence of antibody MOR02965 in PBS. - HuCAL GOLD Antibody Library:
- Antibody library HuCAL GOLD: HuCAL GOLD is a fully synthetic, modular human antibody library in the Fab antibody fragment format. HuCAL GOLD is based on the HuCAL-consensus-antibody genes that were described for the HuCAL-scFv1 library (WO 97/08320; Knappik, (2000), J. Mol. Biol. 296, 57-86; Krebs et al. J Immunol Methods. 2001 Aug. 1; 254(1-2): 67-84). In HuCAL GOLD, all six CDR areas are diversified by the use of so-called trinucleotide mutagenesis (Virnekäs et al. (1994) Nucleic Acids Res. 1994 Dec. 25; 22(25): 5600-7) corresponding to the composition of these areas in human antibodies, while in earlier HuCAL libraries (HuCAL-scFv1 and HuCAL-Fab1), only the CDR3-areas in VH and VL had been diversified corresponding to the natural composition (see Knappik et al., 2000). Moreover, a modified screening process, the so-called CysDisplay (WO 01/05950), is also found in HuCAL GOLD. Vector pMORPH23 that is used for the screening process is found in
FIG. 1 . - Vλ Positions 1 and 2.
- The original HuCAL master genes were constructed with their authentic N-termini: VLλ1: QS (CAGAGC), VLλ2: QS (CAGAGC), and VLλ3: SY (AGCTAT). These sequences are found in WO 97/08320. In the production of the HuCAL-scFv1-library, these two amino acid radicals were changed in “DI” to facilitate the cloning (EcoRI site). These radicals were preserved in the production of HuCAL-Fab1 and HuCAL GOLD. All HuCAL libraries therefore contain VLλ genes with the EcoRV interface GATATC (DI) at the 5′-end. All HuCAL kappa genes (master genes and all genes in the libraries) in any case contain DI at the 5′-end, since these represent the authentic N-termini (WO 97/08320).
-
VH Position 1. - The original HuCAL-master genes were produced with their authentic N-termini: VH1 A, VH1B, VH2, VH4, and VH6 with Q(=CAG) as a first amino acid radical and VH3 as well as VH5 with E(=GAA). The corresponding sequences are found in WO 97/08320. In the cloning of HuCAL-Fab1 as well as the HuCAL GOLD library, the amino acid Q (CAG) was incorporated in all VH genes at this
position 1. - Phagemid Production
- Large amounts of phagemids were produced and concentrated by infection of E. coli TOP10F′ cells from the HuCAL GOLD antibody library or from the maturation libraries by means of helper phages. To this end, the HuCAL GOLD or the maturation libraries (in the TOP10F′ cells) were cultivated in 2×YT medium with 34 μg/ml of chloramphenicol/10 μg/ml of tetracycline/1% glucose at 37° C. up to an OD600 of 0.5. Then, the infection was carried out with VCSM13 helper phages at 37° C. The infected cells were pelletized and resuspended in 2×YT/34 μg/ml of chloramphenicol/10 μg/ml of tetracycline/50 μg/ml of kanamycin/0.25 mmol of IPTG and cultivated overnight at 22° C. The phages were precipitated 2×0 with PEG from the supernatant and harvested by centrifuging (Ausubel (1998) Current Protocols in Molecular Biology. John Wiley Sons, Inc., New York, USA). The phages were resuspended in PBS/20% glycerol and stored at −80° C.
- The phagemid amplification between the individual selection rounds was carried out as follows: log-phase E. coli TG1 cells were infected with selected phages and flattened out on LB-agar plates with 1% glucose/34 μg/ml of chloramphenicol. After incubation overnight, the bacteria colonies were scraped off, newly cultivated and infected with VCSM13 helper phages.
- Primary Selection of Antibodies Against the Dye Fuji 6-4 (ZK203468)
- The purified and concentrated phagemids of the HuCAL GOLD antibody library were used in a standard selection process. As antigens, BSA- or transferrin-coupled ZK203468 were used alternately. The antigens were taken up in PBS and applied at concentrations of 50 μg/ml on Maxisorp™ microtiter plates F96 (Nunc). The Maxisorp plates were incubated overnight at 4° C. (“coating”). After the Maxisorp plates were blocked with 5% milk powder in PBS, about 2E+13 HuCAL GOLD phages were added to the antigen-loaded, blocked-off wells and incubated there overnight or for two hours at room temperature. After several washing steps, which became more stringent with progressive selection rounds, bonded phages were eluted with 20 mmol of DTT or 100 μmol of unconjugated ZK203468. Altogether, three successive selection rounds were carried out, whereby the phage amplification was carried out between the selection rounds, as described above.
- Sub-Cloning of Selected Fab Fragments for Expression
- After the antibody selection that comprises three rounds, the Fab-coding inserts of the isolated HuCAL clones were subcloned in the expression vector pMORPHX9 _MS (see
FIG. 2 ) to facilitate the subsequent expression of the Fab fragments. To this end, the purified plasmid-DNA of the selected HuCAL Fab clones was digested with the restriction enzymes XbaI and EcoRI. The Fab-coding insert was purified and ligated into the correspondingly digested vector pMORPHX9_MS. This cloning step results in the Fab-expressing vector pMORPHX9_Fab_MS. Fab fragments, which are expressed by this vector, carry two C-terminal tags (Myc tag and Strep tag II) for purification and detection. - Screening and Characterization of ZK203468-Binding Fab Fragments
- Several thousand clones were isolated after the selection and sub-cloning and tested by means of ELISA in 384-well format for specific detection of the antigens ZK203468-BSA and -transferrin used in panning. Clones identified in this connection were studied in an inhibition-ELISA for efficient binding of the unconjugated dye.
- This resulted in the parenteral Fab fragments MOR02628 (protein sequences SEQ-ID NO: 1 (VH-CH) and SEQ-ID NO: 2 (VL-CL); DNA sequences SEQ-ID NO: 3 (VH-CH) and SEQ-ID NO: 4 (VL-CL)), MOR02965 (protein sequences SEQ-ID NO: 5 (VH-CH) and SEQ-ID NO: 6 (VL-CL); DNA-sequences SEQ-ID NO: 7 (VH-CH) and SEQ-ID NO: 8 (VL-CL)), and MOR02977 (protein sequences SEQ-ID NO: 9 (VH-CH) and SEQ-ID NO: 10 (VL-CL); DNA sequences SEQ-ID NO: 1 (VH-CH) and SEQ-ID NO: 12 (VL-CL)), and MOR02969 (protein sequences SEQ-ID NO: 13 (VH-CH) and SEQ-ID NO: 14 (VL-CL); DNA sequences SEQ-ID NO: 15 (VH-CH) and SEQ-ID NO: 16 (VL-CL)), that bind efficiently to the non-conjugated dye ZK203468.
- Cloning of the LCDR3 Libraries
- The plasmid-DNA of the four parenteral clones MOR02628, MOR02965, MOR02969 and MOR02977 was digested with the restriction enzymes EcoRI and XbaI, and the complete Fab-insert from expression vector pMORPHX9_MS that was produced was subcloned in the correspondingly cut display vector pMORPH23. This step is necessary to prepare the geneIII, which is used in the presentation of the Fab-fragment on the phage surface. In another step, the four parenteral clones (now in pMORPH23) were digested with BpiI and SphI. In this connection, the LCDR3 region and the constant Clambda area were removed from the vector backbone. The corresponding vector-DNA fragment was isolated and purified. Parallel to this, the complementary BpiI/SphI fragment was isolated from the HuCAL-
Fab 2 library, which contains a diversified LCDR3 region (with a variability from about 3E+8) plus constant Clambda area(=insert-DNA). Several μg of vector-DNA and compatible insert-DNA were ligated in a molar ratio of 1:2 with T4-DNA-ligase and transformed into electrocompetent TOP10F′ cells after a purification step. In this case, library sizes of 5E+8 to approximately 1E+9 clones were achieved per parenteral antibody. - The libraries on which clones MOR02628, MOR02969 and MOR02977 were based were combined (“Pool”). The MOR02965 library was treated separately (“Lead”). As already described, the corresponding phagemids were produced by infection with VCSM13 helper phages by means of these TOP10F′-maturation libraries.
- Antibody Selection of Maxisorp™ Microtiter Plates
- The purified and concentrated phagemids of the “lead” and “pool” libraries were used in a maturation-selection process under stringent conditions (long washing periods, displacement by purified, parenteral Fab proteins). As antigens, BSA- or transferrin-coupled ZK203468 were used alternately. These antigens were taken up in PBS and applied at low concentrations of 100-250 ng/ml on Maxisorp™ microtiter plates F96 (Nunc). The Maxisorp plates were incubated overnight at 4° C. (“coating”). After the Maxisorp plates were blocked with 5% milk powder in PBS, about 2E+13 HuCAL GOLD phages were added to the antigen-loaded, blocked-off wells and incubated there overnight or for two hours at room temperature. To increase the stringency, an additional 100 nm or 500 nm of purified Fab fragments of the parenteral clones were added during this incubation. After several extensive washing steps, bonded phages were eluted with 20 mmol of DTT. Altogether, two successive selection rounds were carried out, whereby the phage amplification was carried out between the selection rounds, as described above.
- Antibody Selections on Neutavidin Strips
- The purified and concentrated phagemids of the “lead” and “pool” libraries were used in addition in a second maturation-selection process under stringent conditions (long washing periods, displacement by purified, parenteral Fab proteins or free dye). As antigens, biotin-conjugated ZK203468 was used (alternately with alkyl or ether linkers). These antigens were taken up in PBS and mixed at low concentrations of 60 or 12 ng/ml with the approximately 2E+11 phages. The antigen-phage solutions were incubated overnight or for 2 hours at room temperature. To increase the stringency, an additional 0.5 μg/ml of purified Fab fragments of the parental clone or 40 nm/ml of ZK203468 was added during this incubation. The solutions that contain antigen-bonded phages were then applied to blocked neutravidin strips and incubated for 30 minutes to make possible the binding to the solid phase via the biotin radical of the antigen. After several washing steps, bonded phages were eluted with 20 mmol of DTT. Altogether, two successive selection rounds were carried out, whereby the phage amplification was carried out between the selection rounds, as described above.
- Sub-Cloning of Selected Fab Fragments for Expression
- After the selection (“maturation”), the Fab-coding inserts of the isolated HuCAL clones were subcloned in the expression vector pMORPHX9_MS to facilitate the subsequent expression. To this end, the purified plasmid-DNA of the selected HuCAL Fab clones was digested with the restriction enzymes XbaI and EcoRI. The Fab-coding insert was purified and ligated into the correspondingly digested vector pMORPHX9_MS. This cloning step results in the Fab-expressing vector pMORPHX9_Fab_MS. Fab fragments, which are expressed by this vector, carry two C-terminal tags (Myc tag and Strep tag II) for purification and detection.
- Identification of Optimized Antibody Fragments
- To identify antibodies with improved affinities for the dye Fuji 6-4, the clones were isolated from the selections and screened in ELISAs in 384-well format. To this end, ZK203468-BSA was applied on the ELISA-microtiter plates. The Fab fragments that are to be examined were added as non-purified bacterial lysates. To study in addition to the binding to the antigen conjugate the binding to the free dye, identical screening plates with bacterial lysate and additional free dye were mixed in two different concentrations. The inhibition of the Fab binding to the solid phase that resulted in this case owing to the unconjugated dye indicated antibodies that do not specifically detect the dye conjugate but rather only the free dye. In this connection, isolated clones were characterized exactly in solution-inhibition tests in the ELISA format and the Luminex device, and their affinities for Fuji 6-4 were determined.
- The following clones showed improved affinities in comparison to the parenteral antibodies:
Name Parenteral Fab LCDR3-Sequence MOR02969 — SSYTYRVGGM MOR03291 MOR02969 ASYDYKSKNI MOR02965 — SSWDSSFSW MOR03263 MOR02965 SSWDVSLEW MOR02977 — QSWTTRPLNR MOR03201 MOR02977 SSWTSYFHIR MOR03267 MOR02977 QAWDSNFKNR MOR03292 MOR02977 QSWAPLFKMR MOR03295 MOR02977 QSWDSALSNR - In summary, the affinity of the parenteral MOR02977 in comparison to MOR03267 could be improved by the factor 140. All other identified clones showed improvements by factors 2-70 in comparison to the respective parenteral Fab.
- Dye-antibody complexes based on antibodies with binding to the indotricarbocyanine dye trisodium-3,3-dimethyl-2-{4-methyl-7-[3,3-dimethyl-5-sulfonato-1-(2-sulfonatoethyl)-3H-indolium-2-yl]hepta-2,4,6-trien-1-ylidene}- 1-(2-sulfonatoethyl)-2,3-dihydro-1H-indole-5-sulfonate, inner salt, were examined (see Examples 1 and 2). Solutions of the concentration of 1 μmol/l of the above-mentioned dye and 2.4 μmol/l of the respective antibody in PBS were produced and incubated for 2 hours at room temperature. The absorption maxima were determined with a spectral photometer (Perkin-Elmer, Lambda2). The fluorescence maxima and fluorescence quantum yields were determined with a SPEX fluorolog (wavelength-dependent sensitivity calibrated by lamp and detector) relative to indocyanine green (Q=0.13 in DMSO, J Chem Eng Data 1977, 22, 379, Bioconjugate Chem 2001, 12, 44). From the absorption and fluorescence maxima, the spectral shifts were calculated relative to the maxima of a solution of the above-mentioned dye without antibodies in PBS (1 μmol/l) (absorption max. 754 nm, fluorescence max. 783 nm, fluorescence quantum yield 10%).
SEQ-ID SEQ-ID SEQ-ID SEQ-ID Parenteral LCDR3- NO. VH NO. VL NO. VH NO. VL Name Fab Sequence Protein Protein DNA DNA MOR02628 AAWDFRKRLN 1 2 3 4 MOR02965 SSWDSSFSW 5 6 7 8 MOR02977 QSWTTRPLNR 9 10 11 12 MOR02969 SSYTYRVGGM 13 14 15 16 MOR02965 — SSWDSSFSW 5 6 7 8 MOR03263 MOR02965 SSWDVSLEW 5 17 7 18 MOR03325 MOR02965 ASWDKSLQW 5 19 7 20 MOR03285 MOR02965 QAWTGSYAT 5 37 7 38 MOR02977 — QSWTTRPLNR 9 10 11 12 MOR03201 MOR02977 SSWTSYFHIR 9 21 11 22 MOR03267 MOR02977 QAWDSNFKNR 9 23 11 24 MOR03268 MOR02977 RSWDSNLSYS 9 25 11 26 MOR03292 MOR02977 QSWAPLFKMR 9 27 11 28 MOR03294 MOR02977 QTWTSSFSSR 9 29 11 30 MOR03295 MOR02977 QSWDSALSNR 9 31 11 32 MOR03309 MOR02977 QTWDHGFTHR 9 33 11 34 MOR03293 MOR02977 SSWTTIYRNR 9 39 11 40 MOR02969 — SSYTYRVGGM 13 14 15 16 MOR03291 MOR02969 ASYDYKSKNI 13 35 15 36 - The results are summarized in the following table:
Absorption Fluorescence Absorption Fluorescence Fluorescence Parenteral Maximum Maximum Shift Shift Quantum Antibody Antibody (nm) (nm) (nm) (nm) Yield (%) Free Dye — 754 783 — — 10.0 MOR02965 — 799 815 45 32 13.0 MOR03263 MOR02965 798 810 44 27 10.0 MOR03325 MOR02965 803 819 49 36 18.0 MOR02977 — 773 788 19 5 24.5 MOR03201 MOR02977 786 804 32 21 21.0 MOR03267 MOR02977 783 802 29 19 38.5 MOR03268 MOR02977 786 805 32 22 30.0 MOR03292 MOR02977 781 800 27 17 25.0 MOR03294 MOR02977 783 803 29 20 22.0 MOR03295 MOR02977 784 803 30 20 23.0 MOR03309 MOR02977 784 803 30 20 21.5 - Cloning of the heavy chain: the “multiple cloning site” of the vector pCDNA3.1+ (Invitrogen) is removed (NheI/ApaI), and a placeholder that is compatible with the restriction interfaces of the HuCAL design is used for the ligation of the leader sequence (NheI/EcoRI), the VH domains of the Fab fragment (MunI/), and the constant immunoglobulin regions (BlpI/ApaI). The leader sequence (EMBL 83133) is equipped with a contact sequence (Kozak, 1987). The constant regions of human IgG (PIR J00228), IgG4 (EMBL K01316), and serum-IgA1 (EMBL J00220) are divided up into overlapping oligonucleotides with a length of, for example, 70 bases. “Silent mutations” are introduced to remove the reaction interfaces that are not compatible with the HuCAL design. The oligonucleotides are linked by “overlap extension-PCR”.
- During the subcloning of the Fab fragments in an IgG molecule, the heavy chain of the Fab fragment is cut out via MfeI/BlpI and ligated into the vector, which is opened with EcoRI/BlpI. EcoRI (g/aattc) and MfeI (c/aattg) have two compatible cohesive ends (aatt), and the sequence of the original MfeI interface in the Fab fragments is changed from: c/aattg to g/aattg to the ligation in the IgG expression vector, by which, on the one hand, both the MfeI interface and the EcoRI interface are destroyed, and, on the other hand, an amino acid exchange from Q (codon: caa) to E (codon: gaa) takes place.
- Cloning of the light chain. The “multiple cloning site” of pCDNA3.1/Zeo+ (Invitrogen) is replaced by two different placeholders. The k-placeholder contains restriction interfaces for the incorporation of a k-leader sequence (NheI/EcoRV), the HuCAL Fab Vk domains (EcoRV/BsiWI), and the constant region of the k-chain (BsiWI/ApaI). The corresponding interfaces in the 1-placeholder are NheI/EcoRV (1-leader), EcoRV/HpaI (V1-domains), and HpaI/ApaI (constant region 1-chain). The k-leader (EMBL Z00022) as well as the 1-leader (EMBL J00241) are both provided with Kozak sequences. The constant regions of human k-(EMBL L00241) and 1-chains (EMBL M18645) are both assembled by “overlap extension-PCR,” as described above.
- Generation of IgG-expressing CHO cells. CHO-K1 cells are co-transfixed with an equimolar mixture of expression vectors for the heavy and light IgG chains. Doubly resistant transfectants are selected with 600 mg/ml of G418 and 300 mg/ml of Zeocin (Invitrogen) followed by limited dilution. The supernatant of individual clones is checked for IgG expression by “capture-ELISA.” Positive clones are cultured in RPMI-1640 medium, which is provided with 10% “ultra-low IgG-FCS” (Life Technologies). After the pH of the supernatant is set at 8.0 and after sterile filtration, the solution is subjected to a standard protein A-column chromatography (Poros 20 A, PE Biosystems).
- Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The preceding preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
- In the foregoing and in the examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated.
- The entire disclosure[s] of all applications, patents and publications, cited herein and of corresponding German application No. 103 31 054.1, filed Jul. 9, 2003, and U.S. Provisional Application Ser. No. 60/487,234, filed Jul. 16, 2003 are incorporated by reference herein.
- The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
- From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/887,231 US20050064512A1 (en) | 2003-07-09 | 2004-07-09 | Emitter-binding peptides that produce a change in the spectral emission properties of the emitter |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10331054.1 | 2003-07-09 | ||
DE2003131054 DE10331054A1 (en) | 2003-07-09 | 2003-07-09 | New emitter-binding peptide, useful for in vitro diagnosis of e.g. antigens, binds to an emitter to change its spectral emission properties, also related nucleic acid, vectors, cells and antibodies |
US48723403P | 2003-07-16 | 2003-07-16 | |
US10/887,231 US20050064512A1 (en) | 2003-07-09 | 2004-07-09 | Emitter-binding peptides that produce a change in the spectral emission properties of the emitter |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050064512A1 true US20050064512A1 (en) | 2005-03-24 |
Family
ID=34066308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/887,231 Abandoned US20050064512A1 (en) | 2003-07-09 | 2004-07-09 | Emitter-binding peptides that produce a change in the spectral emission properties of the emitter |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050064512A1 (en) |
EP (2) | EP1641829A1 (en) |
JP (1) | JP2007526750A (en) |
KR (1) | KR20060067949A (en) |
AT (1) | ATE470678T1 (en) |
AU (1) | AU2004255358A1 (en) |
BR (1) | BRPI0412374A (en) |
CA (1) | CA2531962A1 (en) |
DE (1) | DE502004011269D1 (en) |
EA (1) | EA010289B1 (en) |
HK (1) | HK1094209A1 (en) |
IL (1) | IL172548A0 (en) |
WO (2) | WO2005005482A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110003312A1 (en) * | 2007-12-03 | 2011-01-06 | Carnegie Mellon University | Linked peptide fluorogenic biosensors |
US20110159519A1 (en) * | 2007-01-24 | 2011-06-30 | Carnegie Mellon University | Optical biosensors |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2780845C (en) * | 2009-11-19 | 2014-12-30 | Proteinexpress Co., Ltd. | Fluoroimmunoassay method |
CN102993305B (en) * | 2012-11-16 | 2015-05-13 | 上海赛伦生物技术有限公司 | Humanized anti-human epidemic growth factor receptor (EGFR) antibody as well as encoding gene and application thereof |
US9862682B2 (en) | 2016-01-08 | 2018-01-09 | BroadPharm | Functionalized pegylated cyanine compounds, pharmaceutical compositions, and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837003A (en) * | 1984-09-13 | 1989-06-06 | Mallinckrodt, Inc. | Radiolabeled antibody fragments |
US5569766A (en) * | 1986-04-18 | 1996-10-29 | Carnegie Mellon University | Method for labeling and detecting materials employing arylsulfonate cyanine dyes |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5569587A (en) * | 1986-04-18 | 1996-10-29 | Carnegie Mellon University | Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes |
US6492160B1 (en) * | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
JPH07501451A (en) * | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | Multivalent antigen binding protein |
US6437099B1 (en) * | 1998-01-07 | 2002-08-20 | Hamamatsu Photonics K.K. | Fluorescene—activating antisera and IgG fraction therefrom |
AU2001295042A1 (en) * | 2000-09-13 | 2002-03-26 | The Scripps Research Institute | Anti-stilbene antibodies |
AU2003264497A1 (en) * | 2002-09-19 | 2004-04-08 | Hamamatsu Photonics K.K. | Fluorescence analysis method with the use of fluorescent antibody |
-
2004
- 2004-04-26 WO PCT/EP2004/004403 patent/WO2005005482A1/en active Application Filing
- 2004-04-26 EP EP04729434A patent/EP1641829A1/en not_active Withdrawn
- 2004-07-09 AU AU2004255358A patent/AU2004255358A1/en not_active Abandoned
- 2004-07-09 JP JP2006518165A patent/JP2007526750A/en active Pending
- 2004-07-09 DE DE502004011269T patent/DE502004011269D1/en not_active Expired - Fee Related
- 2004-07-09 EA EA200600158A patent/EA010289B1/en not_active IP Right Cessation
- 2004-07-09 EP EP04740875A patent/EP1641830B1/en active Active
- 2004-07-09 WO PCT/EP2004/007596 patent/WO2005005483A1/en active Application Filing
- 2004-07-09 BR BRPI0412374-3A patent/BRPI0412374A/en not_active IP Right Cessation
- 2004-07-09 AT AT04740875T patent/ATE470678T1/en not_active IP Right Cessation
- 2004-07-09 KR KR1020067000340A patent/KR20060067949A/en not_active Application Discontinuation
- 2004-07-09 US US10/887,231 patent/US20050064512A1/en not_active Abandoned
- 2004-07-09 CA CA002531962A patent/CA2531962A1/en not_active Abandoned
-
2005
- 2005-12-13 IL IL172548A patent/IL172548A0/en unknown
-
2006
- 2006-12-22 HK HK06114088.8A patent/HK1094209A1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837003A (en) * | 1984-09-13 | 1989-06-06 | Mallinckrodt, Inc. | Radiolabeled antibody fragments |
US5569766A (en) * | 1986-04-18 | 1996-10-29 | Carnegie Mellon University | Method for labeling and detecting materials employing arylsulfonate cyanine dyes |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110159519A1 (en) * | 2007-01-24 | 2011-06-30 | Carnegie Mellon University | Optical biosensors |
US8664364B2 (en) | 2007-01-24 | 2014-03-04 | Carnegie Mellon University | Optical biosensors |
US9688743B2 (en) | 2007-01-24 | 2017-06-27 | Carnegie Mellon University | Optical biosensors |
US20110003312A1 (en) * | 2007-12-03 | 2011-01-06 | Carnegie Mellon University | Linked peptide fluorogenic biosensors |
US8426153B2 (en) | 2007-12-03 | 2013-04-23 | Carnegie Mellon University | Linked peptides fluorogenic biosensors |
US10202466B2 (en) | 2007-12-03 | 2019-02-12 | Carnegie Mellon University | Linked peptide fluorogenic biosensors |
Also Published As
Publication number | Publication date |
---|---|
DE502004011269D1 (en) | 2010-07-22 |
HK1094209A1 (en) | 2007-03-23 |
EA010289B1 (en) | 2008-08-29 |
CA2531962A1 (en) | 2005-01-20 |
EP1641830B1 (en) | 2010-06-09 |
BRPI0412374A (en) | 2006-09-05 |
EP1641829A1 (en) | 2006-04-05 |
IL172548A0 (en) | 2006-04-10 |
EP1641830A1 (en) | 2006-04-05 |
JP2007526750A (en) | 2007-09-20 |
AU2004255358A1 (en) | 2005-01-20 |
ATE470678T1 (en) | 2010-06-15 |
WO2005005482A1 (en) | 2005-01-20 |
KR20060067949A (en) | 2006-06-20 |
WO2005005483A1 (en) | 2005-01-20 |
EA200600158A1 (en) | 2006-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7221259B2 (en) | MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING SAME | |
US11629434B2 (en) | Antibody screening methods | |
US7592188B2 (en) | Live cell biosensors | |
Jung et al. | Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting. | |
Colby et al. | Development of a human light chain variable domain (VL) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display | |
Szent-Gyorgyi et al. | Malachite green mediates homodimerization of antibody VL domains to form a fluorescent ternary complex with singular symmetric interfaces | |
JP2016014033A (en) | Quenched dendrimeric dyes for florescence detection | |
US20050064512A1 (en) | Emitter-binding peptides that produce a change in the spectral emission properties of the emitter | |
WO2001096401A1 (en) | METHOD OF CONSTRUCTING scFv ANTIBODY FUSED WITH FLUORESCENT PROTEIN | |
US20050037402A1 (en) | Device and process for direct quantitative in vitro determination of a substance that is contained in a sample | |
US11236386B2 (en) | Method for labeling of aldehyde containing target molecules | |
CN100422214C (en) | Emitter-binding peptides that produce a change in the spectral emission properties of the emitter | |
MXPA06000020A (en) | Emitter-binding peptides causing a change in the spectral emission properties of the emitter | |
Hillig et al. | Fab MOR03268 triggers absorption shift of a diagnostic dye via packaging in a solvent-shielded Fab dimer interface | |
KR102600518B1 (en) | A MULTIVALENT ANTIBODY SPECIFIC FOR BROAD SPECTRUM OF Neisseria gonorrhoeae AND USE OF THE SAME | |
Carvou | Development of a novel immunoassay format for haptens using atrazine as a model molecule |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MORPHOSYS AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHIRNER, MICHAEL;LICHA, KAI;MENRAD, ANDREAS;REEL/FRAME:015990/0190;SIGNING DATES FROM 20040830 TO 20040913 Owner name: SCHERING AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHIRNER, MICHAEL;LICHA, KAI;MENRAD, ANDREAS;REEL/FRAME:015990/0190;SIGNING DATES FROM 20040830 TO 20040913 |
|
AS | Assignment |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING AKTIENGESELLSCHAFT;REEL/FRAME:020110/0334 Effective date: 20061229 Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT,GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING AKTIENGESELLSCHAFT;REEL/FRAME:020110/0334 Effective date: 20061229 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |